Management of kidney cancer has undergone a paradigm shift with the approval of new therapies over the last two decades.Although these drugs have improved clinical outcomes in patients with kidney cancer,there are sti...Management of kidney cancer has undergone a paradigm shift with the approval of new therapies over the last two decades.Although these drugs have improved clinical outcomes in patients with kidney cancer,there are still a large number of patients who do not show objective responses.A multitude of investigators,including those for The Cancer Genome Atlas have biologically characterized and sub-classified kidney cancer.However,we have not been able to identify molecular targets to effectively treat patients with kidney cancer.As we familiarize ourselves with newer drugs for patients with kidney cancer,it is important to understand that these drugs may not work in every patient and instead may expose patients to unnecessary toxic effects along with burdening society with the financial impact.As we head toward the era of“precision medicine”,validated biomarkers are being utilized to guide treatment choices and help identify pathways of resistance in other tumor types.The current review aims at evaluating the progress made so far in this realm for patients with kidney cancer.展开更多
基金the National Center for Advancing Translational Sciences of the National Institutes of Health,under Award Number 2KL2TR001426-05A1.
文摘Management of kidney cancer has undergone a paradigm shift with the approval of new therapies over the last two decades.Although these drugs have improved clinical outcomes in patients with kidney cancer,there are still a large number of patients who do not show objective responses.A multitude of investigators,including those for The Cancer Genome Atlas have biologically characterized and sub-classified kidney cancer.However,we have not been able to identify molecular targets to effectively treat patients with kidney cancer.As we familiarize ourselves with newer drugs for patients with kidney cancer,it is important to understand that these drugs may not work in every patient and instead may expose patients to unnecessary toxic effects along with burdening society with the financial impact.As we head toward the era of“precision medicine”,validated biomarkers are being utilized to guide treatment choices and help identify pathways of resistance in other tumor types.The current review aims at evaluating the progress made so far in this realm for patients with kidney cancer.
